Tropomycin Receptor Kinase Inhibitor,Larotrectinib as a Contributing Factor to anImmune Mediated Polyneuropathy: A Case Report

Authors

Kurt D. Wilhelm, Beaumont Health Resident
Jennifer D. Sloan, Beaumont Health Resident
Nancy M. DeSantis, Beaumont Health

Document Type

Conference Proceeding - Restricted Access

Publication Date

10-2022

Publication Title

PM&R

Volume

14

Issue

S1

First Page

S132

Last Page

S133

Recommended Citation

Wilhelm KD, Sloan JD, DeSantis NM. Tropomycin receptor kinase inhibitor,larotrectinib as a contributing factor to anImmune mediated polyneuropathy: A Case report. PM&R 2022 Oct; 14 (Suppl 1); S132-133.

Comments

American Academy of Physical Medicine and Rehabilitation 2022 Annual Assembly. 2022 Oct 20-23, Baltimore, MD.